Molecular Pathways and Clinical Applications in Advanced Renal Cell Carcinoma - The Virtual Preceptorship

Until recently, few treatment choices were available for patients with advanced and/or metastatic RCC. Disappointing results with standard treatments, coupled with an improved understanding of RCC at the molecular level, has prompted the advancement of a more effective, targeted approach to therapy. The FDA approval of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, sunitinib, sorafenib, and pazopanib; the mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and everolimus; and the monoclonal antibody, bevacizumab, for patients with advanced RCC marks a significant change in the therapeutic approach to kidney cancer. As the treatment armamentarium continues to expand, evidence-based guidelines have been updated to reflect recent changes. This educational activity will utilize a case-based approach to summarize our current understanding of RCC tumor biology and discuss the most recent data supporting treatment recommendations in the first-line setting based on patient characteristics, risk stratification, and management of adverse events commonly associated with targeted therapies. Additionally, second-line options based on previous treatment will be addressed.

Available until August 31, 2011, this activity offers:
Physicians: 1.25 AMA PRA Category 1 Credits^™
Nurses: 1.2 contact hours

This activity is jointly sponsored by SCEPTER™ and Quintiles Medical Education. This activity is co-provided by Global Education Group and SCEPTER™.